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1. Introduction 
Microtubules prepared from mammalian brain by 
polymerization and depolymerlzation cycles consist 
of tubulin and several minor components, o-called 
microtubule-associated proteins (MAPS). The most 
prominent MAPs are two high&fr weight proteins, MAP1 
and MAP2, according to the nomenclature of [I]. 
Microtubule proteins were prepared in buffer A 
from bovine brain by two cycles of polymerization 
and depolymerization [9]. Tubulin and MAPS were 
separated by chromatography on phosphocellulose 
(Whatman P-II) [IO] in buffer A. Before the elution 
of MAPs with 0.5 mM KCl in buffer A, the column 
was washed overnight with buffer A supplemented 
with KCl to a ‘final concentration of 0.1 M. 
MAP2 has an Mr of 280 000-350 000, promotes 
microtubule assembly in vitro and is associated with 
microtubules in cells [2-81. Methods for MAP2 puri- 
fication have been developed in several laboratories 
[2,3,5]. All these use, for removing contaminating 
proteins, a thermoprecipitation stage at which MAP2 
is heated to 85-100°C. So far, purification of native, 
unheated MAP2 has not been reported. 
Hydroxyapatite powder (Bio-Gel HTP, Bio-Rad 
Labs) was hydrated in 50 mM sodium citrate solution 
and equilibrated with buffer B. DEAE-Sephadex 
A-50 (Pharmacia) was equilibrated with buffer A. 
Bio-Gel A-l 5m (Bio-Rad Labs) was equilibrated with 
buffer A containing 0.1 mM PMSF. 
Protein concentration was determined as in [ 111, 
bovine serum albumin being used as a standard. 
The other proteins, MAP1 , having a still higher M,, 
has not been isolated and characterized atall. 
Here we describe a procedure for purification of 
MAP1 from bovine brain and obtaining unheated 
purified MAP2. By the peptide mapping of isolated 
proteins we show also that MAP2 is not a product of 
proteolytic degradation of MAPl. 
SDS-gel electrophoresis was performed according 
to [ 121 on 10% polyacrylamide slab gels at the acryl- 
amide to N,Z#-methylene-bisacrylamide ratio of 100: 1 
(w/w). 
2. Materials and methods 
The following buffers were used: buffer A con- 
taining 50 mM imidazole-HCl (pH2-, 6.7) 50 mM 
KCl, 0.5 mM MgCl?, 0.1 mM EDTA, and 1 mM 
2-mercaptoethanol, and buffer B containing 50 mM 
potassium phosphate (pH*e 6.7) 0.5 mM MgCls, 
1 mM 2-mercaptoethanol, and 0.1 mM PMSF. 
One-dimensional peptide mapping of proteins was 
carried out by the method of [ 131. MAP1 or MAP2 
was incubated with o-chymotrypsin (Sigma) or 
Staphylococcus ureus protease V8 (Miles) for 10 min 
at 37°C in a solution containing 0.0625 M Tris-HCl 
(pH2e 6.8) and 0.1% SDS. Final concentrations of
proteases and MAPs were 0.1 and 0.4 mg/ml, respec- 
tively. Proteolytic products were analysed by SDS 
gel electrophoresis on 15% polyacrylamide slab gels 
at the acrylamide to iVJV’-methylenebisacrylamide 
ratio of 30:0.8 (w/w). 
Abbreviations: EGTA, ethyleneglycol-his@-aminoethyl 
ether)-N,N’-tetraacetate; EDTA, ethylenediaminetetraace- 
tate; PMSF, phenylmethylsulphonylfluoride; SDS, sodium 
dodecylsulphate; MAP, microtubule-associated protein;M,, 
relative molecular mass. 
3. Results 
The starting material for MAP1 and MAP2 purifl- 
cation was the MAP fraction prepared by phospho- 
cellulose chromatography from two-cycled micro- 
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tubule proteins. From 3 kg brain we usually obtained 
50 mg MAPS. All subsequent operations were done at 
o-4Oc. 
MAPs (50 mg in 100 ml) were clarified by centrif- 
ugation (100 000 X g, 30 min), dialyzed against 
buffer A and applied to a DEAE-Sephadex A-50 
column (bed vol. 50 ml) equilibrated with buffer A. 
The column was washed with 250 ml buffer A supple- 
mented with KC1 to 0.25 M then eluted with buffer A 
containing0.5 MKCland0.1 mMPMSF.KCl(0.25 M) 
released from the column low-M, proteins, and 
0.5 M KC1 eluted MAP1 , MAP2 and some other pro- 
teins (fig. 1B). 
All the buffers used further were supplemented 
with 0.1 mM PMSF. KCleluate (0.5 M) from the 
DEAESephadex column was dialyzed against 
buffer B, clarified by centrifugation (100 000 X g, 30 
min) and applied to hydroxyapatite column (bed vol. 
10 ml). The column was washed with 20 ml buffer B 
and step&ted with 0.16 and 0.3 M potassium phos- 
phate buffers (pHae 6.7) containing 0.5 mM MgClz, 
1 mM 2-mercaptoethanol and 0.1 mM PMSF. The 
Fig.1. SDS electrophoretic analysis of the steps in MAP1 and 
MAP2 purification: (A) total MAPS;(B) MAP1 and MAP2 
eluted from DEAE-Sephadex A50 with 0.5 M KCl; (C) MAP2 
eluted from hydroxyapatite with 0.16 M phosphate; (D) 
MAPl-enriched material eluted from hydroxyapatite with 
0.3 M phosphate buffer; (E) pooled MAP1 fraction after gel- 
filtration on Bio-Gel A-15m. 
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fraction eluted from the column with 0.16 M phos- 
phate contained highly purified MAP2 (fig.lC). Only 
trace amounts of several proteins of lower Mr con- 
taminated this MAP2 preparation. From 50 mg total 
MAPs we obtained usually 2-3 mg MAP2. 
The fraction eluted from the hydroxyapatite col- 
A 280 A 
0.04 - 
10 30 50 
FRACTION NUMBER 
Fig.2. Purification of MAP1 by gel-filtration on BioGel 
A-15m. The fraction enriched for MAP1 by hydroxyapatite 
chromatography (10 ml) was applied onto a 2.6 X 90 cm col- 
umn with BioCel A-15m and eluted with buffer A containing 
0.1 mM PMSF at 24 ml/h; fraction vol. 10 ml: (A) elution 
profile; (B) SDS electrophoresis of some individual fractions. 
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Fig.3. One-dimensional peptide maps of MAP1 and MAPZ. 
Digestion of MAP1 (A,C,E,H,J,L) and MAP2 (B,D,F,I,K,M) 
with chymotrypsin (A-F) and Staphylococcus aureus V8 
protease (H-M). Time of hydrolysis was 5 min (A,B,H,I), 
10 min (C,D,J,K) or 20 mm (E,F,L,M). In slots G and N 
chymotrypsin and protease V8, respectively, were applied. 
umn with 0.3 M phosphate contained predominantly 
MAP1 (tIg.lD). Further purification of MAP1 was 
achieved by gel filtration on a Bio-Gel A-l 5m column 
(2.6 X 90 cm). The elution profile and the polypep- 
tide composition of some fractions, as revealed by 
SDS-gel electrophoresis, are shown in tig.2. The frac- 
tions that contained purified MAP1 (the left part of 
the main protein peak, fractions 30-32) were pooled 
and concentrated on a small phosphocelhrlose column 
(bed vol. l-2 ml). 
As shown in fig.1 E, the pooled MAP1 preparation 
contained, besides MAPl, barely detectable amounts 
of MAP2 and of 2 polypeptides of Mr < 40 000. The 
yield of MAP1 was l-l 5 mg from 50 mg total MAPS. 
High-M, MAPs have been reported to be sensitive 
to brain proteases [ 14,151. Our data agree well with 
these observations. As revealed by electrophoresis 
(not shown), purified MAP1 and MAP2 completely 
degraded in 4-6 days at 4’C in the absence of pro- 
tease inhibitors. This circumstance made it difficult to 
isolate and store MAP1 and MAP2, and we attempted 
to select an appropriate inhibitor preventing MAP1 
and MAP2 proteolysis. Among the inhibitors tested 
(EGTA, 0.1 mM; leupeptin, 5 pg/ml; PMSF, 0.1 mM) 
it was only PMSF that was effective. 
In view of possible proteolysis of MAPS during 
their purification the question arose whether MAP2, 
having a lower Mr than MAP1 , might be a product of 
MAP1 proteolytic cleavage. A component similar to 
MAP2 in its electrophoretic mobility was really 
observed sometimes among the products of MAP1 
degradation by an endogenous protease in the absence 
of PMSF. So we compared one-dimensional peptide 
maps of the purified MAP1 and MAP2. The peptide 
patterns resulting from chymotrypsin or S. uur-eus 
protease Vg digestion of the 2 MAPs are shown in 
flg.3. The MAP2 patterns differed strongly from that 
of MAP1 , which indicates that these proteins have 
different primary structures and that MAP2 is not a 
product of MAP1 degradation. 
4. Conclusions 
We have developed, for the first time, a method 
for purification of brain microtubule protein MAPI. 
The method permits us to isolate also the other high- 
&f, microtubule-associated protein, MAP2. Although 
MAP2 purification has been reported earlier, our pro- 
cedure is the first one that does not include heating 
the protein to a high temperature. 
The isolation of MAP1 makes possible a direct 
investigation of its physico-chemical nd functional 
activities. We have begun such an investigation and 
report in [ 161 that purified MAP1 is able to promote 
microtubule assembly in vitro. 
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